Volume 21, Number 3—March 2015
Research
Risk Factors for Death from Invasive Pneumococcal Disease, Europe, 2010
Table 2
Associations between invasive pneumococcal disease study variables and death, Europe, 2010*
Variable |
Outcome
|
p value† | |
---|---|---|---|
Nonfatal, no. (%) | Fatal, no. (%) | ||
Sex | |||
F | 1,147 (91.3) | 110 (8.8) | 0.631 |
M
|
1,498 (90.7)
|
153 (9.3)
|
|
Age group, y | |||
<5 | 557 (97.7) | 13 (2.3) | |
5–64 | 1,123 (91.9) | 99 (8.1) | <0.001 |
>65
|
956 (86.3)
|
152 (13.7)
|
|
Clinical presentation | |||
Nonmeningitis | 1,571 (91.2) | 151 (8.8) | <0.001 |
Meningitis
|
329 (84.1)
|
62 (15.9)
|
|
Serotype | |||
PCV13-specific‡ | 1,155 (93.5) | 80 (6.5) | <0.001 |
PCV7 | 444 (85.9) | 73 (14.1) | |
Non-PCV
|
1,058 (90.5)
|
111 (9.5)
|
|
Antimicrobial susceptibility | |||
Penicillin | |||
Susceptible | 1,815 (93.1) | 134 (6.9) | |
Nonsusceptible§ | 106 (86.9) | 16 (13.1) | |
Erythromycin | 0.010 | ||
Susceptible | 1,464 (93.1) | 109 (6.9) | |
Nonsusceptible | 451 (92.8) | 35 (7.2) |
*PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV;
†Pearson χ2 test.
‡Serotypes contained in PCV13 but not in PCV7.
§Either resistant or intermediate resistance.
1Members of the Invasive Pneumococcal Disease Study Group who contributed data are listed at the end of this article.